Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities
The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…
Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M
The deal covers the U.S., Canada, European Union, Great Britain, And Israel.
Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating
Reported Late Thursday March 9, MediciNova Announces Additional Extension Of BARDA Contract To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury; Contract Was Amended To Extend The Period Of Performance Until May 31, 2…
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with
Bill Gates Is Not Expecting You To Give Up Meat, Even Though The Planet Could Benefit From It — Here’s Why
In a lecture given last week at the fifth Ramnath Goenka Lecture in India, former Microsoft CEO and…
FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication
William Blair has initiated coverage on Mesoblast Ltd (NASDAQ:MESO) with an Outperform rating and a price target of $8. Mesoblast’s lead product,…
Clene’s Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows
Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…
AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…